BCR and acute lymphoblastic leukemia: Dasatinib's main therapeutic action in Ph/Ph-like ALL is inhibition of BCR-ABL, but it also acts on multiple other tyrosine kinases and receptor tyrosine kinases, including Src family kinases, c-Kit, platelet-derived growth factor receptor, and others [13].